GLP1R and diabetes mellitus: Meanwhile, semaglutide, a GLP-1 receptor agonist, has demonstrated weight reduction and glycemic control benefits in KTRs with diabetes or metabolic syndrome, with no significant adverse impact on graft function in small studies.